Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, open-label trial to evaluate the efficacy and safety of MGCD0103 [MGCD 0103] administered in combination with azacitidine (Vidaza) to subjects with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma, and to evaluate the pharmacokinetics of MGCD0103 and FB-MGCD0103

Next Previous
Trial Profile

A phase 2, open-label trial to evaluate the efficacy and safety of MGCD0103 [MGCD 0103] administered in combination with azacitidine (Vidaza) to subjects with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma, and to evaluate the pharmacokinetics of MGCD0103 and FB-MGCD0103

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Mocetinostat (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Celgene Corporation; Mirati Therapeutics; Pharmion Corporation

Most Recent Events

  • 08 Dec 2008 Status changed from suspended to discontinued, based on information from ClinicalTrials.gov. This trial has been closed as Celgene has terminated its collaborative agreement, with MethylGene, for the development of MGCD0103.
  • 22 Sep 2008 Celgene Corporation reported as a company Affiliate and Sponsor by ClinicalTrials.gov.
  • 23 Jul 2008 Status changed from recruiting to in progress, as reported on clinicaltrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top